QSAM Biosciences (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, has announced a partnership with RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the country. The two companies have a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam(R) (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children. The partnership is the latest in a series of RLS efforts to expand its industry-leading CDMO business and clinical trial capability with radiopharmaceutical partners across the United States. According to the announcement, QSAM is enrolling patients with metastatic bone cancer in a phase I clinical trial evaluating CycloSam; the trial will be conducted in three clinical sites in the United States with additional sites anticipated.
The agreement supports the rapid and efficient preparation of CycloSam doses in compliance with strict industry quality control systems, for patient administration in both current and future clinical trials; the agreement includes an option to expand to commercial scale if CycloSam is approved by the FDA. “We believe the short half-life of Samarium-153 with respect to patient exposure, toxicity and tolerability makes it an ideal drug to treat bone cancers,” said QSAM CEO and cofounder Douglas R. Baum in the press release. “The ability to meet the potential demand requires a pharmacy network capable of preparing and timely delivering patient doses for administration. The RLS network of 31 radiopharmacies across 18 states adds significant geographic coverage and infrastructure to our supply chain, along with an unprecedented level of on-the-ground expertise and credibility as the only accredited radiopharmacy network in the country. Choosing RLS as a partner will not only bolster our current and near-term clinical trials, but it may also provide the initial groundwork for eventual commercial supply and distribution.”
To view the full press release, visit https://ibn.fm/dkmNf
About QSAM Biosciences Inc.
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases. QSAM’s initial technology, CycloSam (Samarium-153 DOTMP), is a clinical-stage, bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space that also developed the FDA-approved Quadramet(R) (Samarium-153 EDTMP) radiopharmaceutical product. The QSAM team has designed the CycloSam product with the goal of overcoming the limitations of the Quadramet(R) (Samarium-153 EDTMP) product and potentially expand the FDA-approved indications. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. CycloSam has demonstrated preliminary safety and efficacy in animal studies and a single-patient, FDA-cleared human trial performed in 2020 at the Cleveland Clinic. This nuclear technology uses low specific activity Samarium-153 (resulting in far less undesirable europium impurity) and DOTMP, which is highly targeted and actively drawn to areas of high bone turnover, making it, in management’s opinion based on scientific studies, an ideal agent to treat primary and secondary bone cancers. Since CycloSam delivers targeted radiation selectively to the skeletal system and to bone tumors, it is also believed to be a great potential candidate for future effectiveness in clinical trials in bone marrow ablation as preconditioning for bone marrow transplantation as well as its future clinical trials in procedures to reduce external beam radiation to bone tumors. This multipatented drug candidate utilizes a radioisotope previously approved by the FDA, combined with a novel targeting chelant, DOTMP, that has demonstrated preliminary increased efficacy and decreased side effects in animal models and veterinary treatment of bone cancer in dogs. Further, CycloSam utilizes a streamlined, just-in-time manufacturing process that is already in place. Given these factors, management believes there is a strong pathway to commercialization for CycloSam. For more information about the company, please visit www.QSAMBio.com
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
